Results 311 to 315 of about 554,589 (315)

Dopamine agonist therapy in early Parkinson's disease.

Cochrane Database of Systematic Reviews, 2008
BACKGROUND Dopamine agonists are being used increasingly as first line treatment for Parkinson's disease, but there remains uncertainty about their clinical and cost-effectiveness relative to levodopa.
R. Stowe, N. Ives, C. Clarke, J. V. Hilten, J. Ferreira, R. Hawker, L. Shah, K. Wheatley, R. Gray   +8 more
semanticscholar   +1 more source

Dopamine Agonist Withdrawal Syndrome: Implications for Patient Care

Drugs & Aging, 2013
M. Nirenberg
semanticscholar   +1 more source

Low levels of PRB3 mRNA are associated with dopamine-agonist resistance and tumor recurrence in prolactinomas

Journal of Neuro-Oncology, 2013
Fei Wang, Hua Gao, Chuzhong Li, J. Bai, R. Lu, Lei Cao, Yongtu Wu, Lichuan Hong, Yonggang Wu, Xiaolei Lan, Yazhuo Zhang   +10 more
semanticscholar   +1 more source

Risk of Cardiac Valve Regurgitation with Dopamine Agonist use in Parkinson’s Disease and Hyperprolactinaemia

Drug Safety, 2012
G. Trifirò, M. Mokhles, J. Dieleman, E. M. van Soest, K. Verhamme, G. Mazzaglia, R. Herings, Cynthia de Luise, D. Ross, G. Brusselle, A. Colao, W. Haverkamp, R. Schade, G. Van Camp, R. Zanettini, M. Sturkenboom   +15 more
semanticscholar   +1 more source

The central effects of a novel dopamine agonist.

European Journal of Pharmacology, 1978
P. Setler, H. Sarau, C. Zirkle, H. L. Saunders   +3 more
semanticscholar   +1 more source